Checkpoint Therapeutics Inc CKPT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024
-
Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
-
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
-
Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates
-
Checkpoint Therapeutics Shares Rise After FDA Accepts Resubmission of Cosibelimab
-
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
-
GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research
-
Checkpoint Therapeutics Reaches BLA Alignment With FDA for Cosibelimab
Trading Information
- Previous Close Price
- $2.18
- Day Range
- $2.18–2.23
- 52-Week Range
- $1.36–3.62
- Bid/Ask
- $2.19 / $2.23
- Market Cap
- $99.94 Mil
- Volume/Avg
- 247,458 / 383,903
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 832.08
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 23
- Website
- https://www.checkpointtx.com
Comparables
Valuation
|
Metric
|
CKPT
|
PRLD
|
CGON
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 0.60 | 4.42 |
Price/Sales | 832.08 | — | 244.06 |
Price/Cash Flow | — | — | — |
Price/Earnings
CKPT
PRLD
CGON
Financial Strength
|
Metric
|
CKPT
|
PRLD
|
CGON
|
|---|---|---|---|
Quick Ratio | 0.23 | 7.71 | 46.66 |
Current Ratio | 0.26 | 7.83 | 47.57 |
Interest Coverage | — | — | — |
Quick Ratio
CKPT
PRLD
CGON
Profitability
|
Metric
|
CKPT
|
PRLD
|
CGON
|
|---|---|---|---|
Return on Assets (Normalized) | −479.97% | −40.98% | −15.24% |
Return on Equity (Normalized) | — | −46.70% | −26.61% |
Return on Invested Capital (Normalized) | — | −44.57% | −25.60% |
Return on Assets
CKPT
PRLD
CGON
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Dqdgqjfyxs | Jwqx | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Lnwsvskv | Hlnbvnz | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Hzzglxwb | Bzffv | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Kxqxdby | Rnrtz | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Xkkrlrvhw | Gtd | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Fdhwtcmx | Lxkjx | $29.2 Bil | |||
| Moderna Inc
MRNA
| Dxpxdlqr | Mfm | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Klftjqlvk | Rkphj | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Lcttyrsh | Dldkxd | $13.2 Bil | |||
| Incyte Corp
INCY
| Vwkkjlfk | Jbmlr | $13.0 Bil |
United States